Strides Pharma Science (STAR) Aktievy
Strides Pharma Science Limited utvecklar, tillverkar och säljer läkemedelsprodukter i Afrika, Australien, Nordamerika, Europa, Asien, Indien och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 4/6 |
| Framtida tillväxt | 5/6 |
| Tidigare resultat | 4/6 |
| Finansiell hälsa | 5/6 |
| Utdelningar | 3/6 |
STAR Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Strides Pharma Science Limited Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | ₹1,126.80 |
| 52 veckors högsta | ₹1,231.00 |
| 52 veckors lägsta | ₹768.65 |
| Beta | 0.34 |
| 1 månads förändring | 7.87% |
| 3 månaders förändring | 14.86% |
| 1 års förändring | 27.29% |
| 3 års förändring | 155.02% |
| 5 års förändring | 45.66% |
| Förändring sedan börsintroduktionen | 25.81% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Jul 03
STAR: Upcoming Partnership Decision Will Support Stronger Forward Outlook
Analysts have raised their price target on Strides Pharma Science from ₹1,119 to ₹1,254, citing updated assumptions for revenue growth, profit margins and future P/E multiples reflected in the latest model inputs. What’s in the News for Strides Pharma Science Board meeting scheduled on Jun 27, 2026, at 15:00 IST to consider the partnership between Strides Pharma Science and Ascent Capital related to Pivot Path.Uppdatering av berättelse • Jun 16
STAR: Upcoming Results And Dividend Decision Will Guide Balanced Outlook
Analysts have reiterated their ₹1,119 price target on Strides Pharma Science, citing only minor adjustments to revenue growth, profit margin and future P/E assumptions that support maintaining the existing valuation view. What’s in the News for Strides Pharma Science A Board of Directors meeting is scheduled for May 18, 2026 at 12:30 Indian Standard Time to review and approve audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026 (source: company board meeting disclosure).Uppdatering av berättelse • Jun 01
STAR: Upcoming Results, Dividend Proposal And Auditor Change Will Shape Balanced Outlook
Analysts have kept the price target for Strides Pharma Science broadly steady at about ₹1,119, citing only small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E that do not materially change their valuation view. What's in the News A board meeting is scheduled on May 18, 2026 at 12:30 Indian Standard Time to review and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Uppdatering av berättelse • May 17
STAR: Upcoming Results And Dividend Decision Will Shape Fairly Valued Outlook
Analysts have raised their price target on Strides Pharma Science from ₹1,078.50 to ₹1,264.00, citing updated assumptions that include higher projected revenue growth, a slightly stronger profit margin profile, a modestly lower discount rate, and a somewhat higher future P/E multiple. What's in the News A board meeting is scheduled on May 18, 2026, to review and approve the audited standalone and consolidated financial results for the quarter and full year ended March 31, 2026 (Key Developments).Recent updates
Uppdatering av berättelse • Jul 03
STAR: Upcoming Partnership Decision Will Support Stronger Forward Outlook
Analysts have raised their price target on Strides Pharma Science from ₹1,119 to ₹1,254, citing updated assumptions for revenue growth, profit margins and future P/E multiples reflected in the latest model inputs. What’s in the News for Strides Pharma Science Board meeting scheduled on Jun 27, 2026, at 15:00 IST to consider the partnership between Strides Pharma Science and Ascent Capital related to Pivot Path.Uppdatering av berättelse • Jun 16
STAR: Upcoming Results And Dividend Decision Will Guide Balanced Outlook
Analysts have reiterated their ₹1,119 price target on Strides Pharma Science, citing only minor adjustments to revenue growth, profit margin and future P/E assumptions that support maintaining the existing valuation view. What’s in the News for Strides Pharma Science A Board of Directors meeting is scheduled for May 18, 2026 at 12:30 Indian Standard Time to review and approve audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026 (source: company board meeting disclosure).Uppdatering av berättelse • Jun 01
STAR: Upcoming Results, Dividend Proposal And Auditor Change Will Shape Balanced Outlook
Analysts have kept the price target for Strides Pharma Science broadly steady at about ₹1,119, citing only small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E that do not materially change their valuation view. What's in the News A board meeting is scheduled on May 18, 2026 at 12:30 Indian Standard Time to review and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Uppdatering av berättelse • May 17
STAR: Upcoming Results And Dividend Decision Will Shape Fairly Valued Outlook
Analysts have raised their price target on Strides Pharma Science from ₹1,078.50 to ₹1,264.00, citing updated assumptions that include higher projected revenue growth, a slightly stronger profit margin profile, a modestly lower discount rate, and a somewhat higher future P/E multiple. What's in the News A board meeting is scheduled on May 18, 2026, to review and approve the audited standalone and consolidated financial results for the quarter and full year ended March 31, 2026 (Key Developments).
Uppdatering av berättelse • Apr 28
STAR: Higher Revenue And Margin Assumptions Will Support Stronger Returns Ahead
Analysts have maintained their price target for Strides Pharma Science at ₹1,409, citing updated assumptions that reflect slightly higher revenue growth and profit margin expectations, along with a modestly lower future P/E multiple in their models. Valuation Changes Fair Value: Model fair value remains unchanged at ₹1,409.0 per share.Uppdatering av berättelse • Apr 13
STAR: Upcoming Results Meeting And Revised Assumptions Will Support Bullish Thesis
Analysts have lifted their price target on Strides Pharma Science from ₹1,085 to ₹1,119, pointing to revised assumptions that include slightly higher revenue growth, a modestly lower profit margin and a small uplift in the future P/E multiple. What's in the News A board meeting is scheduled for January 30, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, along with other agenda items (company filing).Uppdatering av berättelse • Mar 30
STAR: Higher Revenue Assumptions Will Support Stronger Profit Margins Ahead
Analysts have raised their price target on Strides Pharma Science from ₹1,220 to ₹1,409, citing updated assumptions for revenue growth, profit margins and future P/E that collectively support a higher fair value estimate under a slightly lower discount rate. What's in the News A board meeting is scheduled for January 30, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, along with other matters (company filing).Uppdatering av berättelse • Mar 16
STAR: Future Earnings Meeting And Margin Outlook Will Support Bullish Thesis
Analysts have lifted their price target on Strides Pharma Science from ₹937 to ₹1,085, citing updated assumptions for revenue growth, profit margins and the future P/E multiple, as well as a slightly lower discount rate. What's in the News The board has scheduled a meeting on January 30, 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, along with other matters (company filing).Uppdatering av berättelse • Sep 05
Affordable Generics And Digital Trends Will Broaden Global Healthcare Reach
With both Net Profit Margin and Revenue Growth forecasts remaining stable, analysts made no substantive changes to their outlook, resulting in the consensus price target for Strides Pharma Science holding steady at ₹1078. What's in the News Board meeting scheduled to consider and approve Q1 FY26 unaudited financial results, share allotment, and amendments to the company's fair disclosure policy.
Ny berättelse • Feb 10
US Product Launches And ESG Leadership Will Strengthen Future Market Position
Streamlined focus on high-margin operations and U.S. market expansion indicate a strong growth trajectory and improved future earnings.Analysartikel • Nov 01
Strides Pharma Science's (NSE:STAR) Solid Earnings Are Supported By Other Strong Factors
Even though Strides Pharma Science Limited's ( NSE:STAR ) recent earnings release was robust, the market didn't seem to...Analysartikel • Oct 21
Why Investors Shouldn't Be Surprised By Strides Pharma Science Limited's (NSE:STAR) 27% Share Price Surge
Despite an already strong run, Strides Pharma Science Limited ( NSE:STAR ) shares have been powering on, with a gain of...Analysartikel • Aug 14
After Leaping 29% Strides Pharma Science Limited (NSE:STAR) Shares Are Not Flying Under The Radar
Despite an already strong run, Strides Pharma Science Limited ( NSE:STAR ) shares have been powering on, with a gain of...Analysartikel • Apr 04
Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)
With a median price-to-sales (or "P/S") ratio of close to 2.4x in the Pharmaceuticals industry in India, you could be...Analysartikel • Feb 29
Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysartikel • Dec 23
Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story
Strides Pharma Science Limited ( NSE:STAR ) shareholders have had their patience rewarded with a 31% share price jump...Analysartikel • Sep 26
We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysartikel • Jun 08
Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysartikel • Aug 02
Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
Last week saw the newest quarterly earnings release from Strides Pharma Science Limited ( NSE:STAR ), an important...Analysartikel • Jun 25
Is Strides Pharma Science (NSE:STAR) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Aktieägarnas avkastning
| STAR | IN Pharmaceuticals | IN Marknad | |
|---|---|---|---|
| 7D | 4.1% | 3.3% | 1.0% |
| 1Y | 27.3% | 12.6% | -1.4% |
Avkastning vs industri: STAR översteg Indian Pharmaceuticals branschen som gav 12.6 % under det senaste året.
Avkastning vs Marknaden: STAR översteg Indian marknaden som gav -1.4 % under det senaste året.
Prisvolatilitet
| STAR volatility | |
|---|---|
| STAR Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.3% |
| 10% least volatile stocks in IN Market | 4.1% |
Stabil aktiekurs: STAR har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för Indian.
Volatilitet över tid: STAR s veckovolatilitet ( 5% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1990 | 3,301 | Badree Komandur | www.strides.com |
Strides Pharma Science Limited utvecklar, tillverkar och säljer läkemedelsprodukter i Afrika, Australien, Nordamerika, Europa, Asien, Indien och internationellt. Verksamheten bedrivs genom två segment, Pharmaceutical och Biopharmaceutical. Företaget erbjuder generiska läkemedel i olika former, t.ex. tabletter, hårda och mjuka gelatinkapslar, dospåsar och vätskor, samt nässpray, geler, pulver, fasta substanser, salvor och krämer.
Strides Pharma Science Limited Sammanfattning av grunderna
| STAR grundläggande statistik | |
|---|---|
| Börsvärde | ₹103.86b |
| Vinst(TTM) | ₹5.56b |
| Intäkter(TTM) | ₹48.59b |
18.7x
P/E-förhållande2.1x
P/S-förhållandeÄr STAR övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| STAR resultaträkning (TTM) | |
|---|---|
| Intäkter | ₹48.59b |
| Kostnad för intäkter | ₹19.59b |
| Bruttovinst | ₹29.00b |
| Övriga kostnader | ₹23.44b |
| Intäkter | ₹5.56b |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | 60.34 |
| Bruttomarginal | 59.69% |
| Nettovinstmarginal | 11.45% |
| Skuld/egenkapitalförhållande | 53.0% |
Hur har STAR utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
0.4%
Aktuell utdelningsavkastning8%
UtbetalningskvotFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/05 02:18 |
| Aktiekurs vid dagens slut | 2026/07/03 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2026/03/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Strides Pharma Science Limited bevakas av 15 analytiker. 3 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Aditya Khemka | Ambit Capital |
| Harith Ahamed | Avendus Spark |
| Prakash Agarwal | Axis Capital Limited |